Where Will AbbVie Be in 5 Years?
A lot has changed for (NYSE: ABBV) over the past five years. Notably, the biotech company's Humira, once its biggest growth driver and the world's best-selling drug, lost patent exclusivity in the U.S. in 2023. Despite that setback, AbbVie has produced solid returns over the last half a decade.
But can the drugmaker maintain that momentum through 2031? Let's find out how things might unfold for AbbVie over the next five years.
Image source: Getty Images.
Source Fool.com
AbbVie Inc. Stock
€177.10
-0.250%
With 32 Buy predictions and not a single Sell prediction AbbVie Inc. is an absolute favorite of our community.
With a target price of 209 € there is a slightly positive potential of 18.01% for AbbVie Inc. compared to the current price of 177.1 €.
